NO20023123L - Fremgangsmåter for pulmonal avlevering av interleukin-2 - Google Patents

Fremgangsmåter for pulmonal avlevering av interleukin-2

Info

Publication number
NO20023123L
NO20023123L NO20023123A NO20023123A NO20023123L NO 20023123 L NO20023123 L NO 20023123L NO 20023123 A NO20023123 A NO 20023123A NO 20023123 A NO20023123 A NO 20023123A NO 20023123 L NO20023123 L NO 20023123L
Authority
NO
Norway
Prior art keywords
interleukin
methods
pulmonary delivery
pulmonary
delivery
Prior art date
Application number
NO20023123A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023123D0 (no
Inventor
Bao-Lu Chen
Maninder Hora
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO20023123D0 publication Critical patent/NO20023123D0/no
Publication of NO20023123L publication Critical patent/NO20023123L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20023123A 1999-12-30 2002-06-27 Fremgangsmåter for pulmonal avlevering av interleukin-2 NO20023123L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17392299P 1999-12-30 1999-12-30
US72481000A 2000-11-28 2000-11-28
PCT/US2000/035452 WO2001049274A2 (fr) 1999-12-30 2000-12-27 Procedes d'administration pulmonaire d'interleukine-2

Publications (2)

Publication Number Publication Date
NO20023123D0 NO20023123D0 (no) 2002-06-27
NO20023123L true NO20023123L (no) 2002-08-07

Family

ID=26869690

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023123A NO20023123L (no) 1999-12-30 2002-06-27 Fremgangsmåter for pulmonal avlevering av interleukin-2

Country Status (15)

Country Link
US (2) US20030198602A1 (fr)
EP (1) EP1244432A2 (fr)
JP (1) JP2003519175A (fr)
CN (1) CN100333790C (fr)
AU (1) AU783795B2 (fr)
BR (1) BR0016879A (fr)
CA (1) CA2395887A1 (fr)
CZ (1) CZ20022265A3 (fr)
HU (1) HUP0204136A3 (fr)
IL (2) IL150461A0 (fr)
NO (1) NO20023123L (fr)
NZ (1) NZ520379A (fr)
PL (1) PL356641A1 (fr)
SK (1) SK11142002A3 (fr)
WO (1) WO2001049274A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP2003524646A (ja) * 2000-01-25 2003-08-19 エアロファーム テクノロジー インコーポレイテッド 医薬エアゾール製剤
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
AU2002335046A1 (en) * 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
EP1494732B1 (fr) 2002-03-20 2008-01-30 MannKind Corporation Appareil d'inhalation
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
EP1589949B1 (fr) * 2003-01-08 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Compositions lyophilisees stabilisees renfermant un inhibiteur de la voie du facteur tissulaire ou des variantes d'un inhibiteur de la voie du facteur tissulaire
EP1803445A3 (fr) * 2003-01-08 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Compositions lyophilisées stabilisées renfermant un inhibiteur de la voie du facteur tissulaire ou des variantes d'un inhibiteur de la voie du facteur tissulaire
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
JP4147235B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
WO2006130943A1 (fr) * 2005-06-10 2006-12-14 The Governors Of The University Of Alberta Formule de poudre sechee inhalable comprenant des nanoparticules chargees d'un medicament
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CN101125199B (zh) * 2006-08-15 2010-07-21 北京四环生物制药有限公司 白介素2作为制备治疗鼻炎药物的应用
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (fr) 2008-06-20 2021-12-29 MannKind Corporation Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et methode de simulation d'efforts d'inhalation
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
EP2694402B1 (fr) 2011-04-01 2017-03-22 MannKind Corporation Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
EP2550863A1 (fr) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Particules contenant une matière active à base de polyacrylate
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
EP2872205B1 (fr) 2012-07-12 2017-02-08 MannKind Corporation Systèmes de libération de médicament en poudre sèche
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (fr) 2013-03-15 2014-09-18 Mannkind Corporation Compositions de dicétopipérazine microcristallines et procédés
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (fr) 2013-08-05 2020-10-07 MannKind Corporation Appareil d'insufflation
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CA3001429C (fr) * 2015-10-22 2023-07-11 Iltoo Pharma Compositions pharmaceutiques d'il-2
EP3478264B1 (fr) * 2016-06-30 2025-11-19 Philip Morris Products S.A. Particules et compositions de nicotine
WO2018081213A1 (fr) * 2016-10-25 2018-05-03 Marquette University Supports et formulations pulvérulentes pour dents avulsées et tissus explantés comprenant des fibroblastes
CA3172871A1 (fr) * 2020-05-11 2021-11-18 Francisca O. GBORMITTAH Compositions de polypeptides de fusion d'il-2 et leurs procedes de fabrication et d'utilisation
US12024559B2 (en) 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
WO2022100686A1 (fr) * 2020-11-13 2022-05-19 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un variant ou un dérivé d'il-2 humaine et son utilisation
CN121466042A (zh) * 2026-01-09 2026-02-06 苏州市立医院 一种吸入用药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4927850A (en) * 1988-04-08 1990-05-22 Bayless Robert K Antioxidant compositions and methods for ameliorating inflammatory symptoms of respiratory disease
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
DK0462305T3 (da) * 1990-06-21 1995-04-24 Huland Edith Anvendelse af cytokinholdige aerosoler såvel som cytokholdige aerosoler i sig selv
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
FI960253A7 (fi) * 1993-07-19 1996-03-18 Amgen Inc Aerosolisoitujen proteiinien stabilointi
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物

Also Published As

Publication number Publication date
CN100333790C (zh) 2007-08-29
CZ20022265A3 (cs) 2004-01-14
EP1244432A2 (fr) 2002-10-02
US20030198602A1 (en) 2003-10-23
NZ520379A (en) 2004-05-28
PL356641A1 (en) 2004-06-28
NO20023123D0 (no) 2002-06-27
AU2603701A (en) 2001-07-16
HUP0204136A3 (en) 2005-09-28
HUP0204136A2 (hu) 2003-03-28
CA2395887A1 (fr) 2001-07-12
WO2001049274A3 (fr) 2002-02-14
AU783795B2 (en) 2005-12-08
CN1437466A (zh) 2003-08-20
JP2003519175A (ja) 2003-06-17
IL150461A0 (en) 2002-12-01
WO2001049274A2 (fr) 2001-07-12
IL150461A (en) 2008-11-26
US20080003294A1 (en) 2008-01-03
BR0016879A (pt) 2002-12-03
SK11142002A3 (sk) 2004-09-08

Similar Documents

Publication Publication Date Title
NO20023123D0 (no) Fremgangsmåter for pulmonal avlevering av interleukin-2
NO20016116D0 (no) Substituerte heterocykliske fuserte gamma-karboliner
DE60037213D1 (de) Verwendung von Reinigungsgas
EP1147107A4 (fr) Inhibiteurs d'angiogenese
DK1261585T3 (da) Substituerede indol-Mannichbaser
DE60007697D1 (de) Triazolderivate
DE60025732D1 (de) Frequenzmessgerät
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
FI990509A0 (fi) Häiriönpoistomenetelmä
NO20001134D0 (no) FremgangsmÕte for fremstilling av VCM
EE200100537A (et) Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena
NO20022682D0 (no) Heterosykliske derivater
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20022446D0 (no) Etere av O-desmetyl-venlafaxine
FI20010892A0 (fi) Menetelmä ksylitolin valmistamiseksi
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
PT1030319E (pt) Nucleo toroidal
DE50001036D1 (de) Keramischer Verdampfer
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
AR027857A1 (es) Nucleo absorbente mejorado
NO991585D0 (no) Trekkanordning
FI991413A0 (fi) Yhteyden pystytysmenetelmä
EE200000132A (et) Seade keramsiitgranulaadi valmistamiseks

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application